{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T19:47:06Z","timestamp":1766087226243},"reference-count":21,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Science and Technology Project","award":["2013KN-01"],"award-info":[{"award-number":["2013KN-01"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.prp.2017.10.016","type":"journal-article","created":{"date-parts":[[2017,10,19]],"date-time":"2017-10-19T10:14:58Z","timestamp":1508408098000},"page":"263-267","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: A pilot study"],"prefix":"10.1016","volume":"214","author":[{"given":"Gen-He","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng-Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long-Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Qing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo-Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2017.10.016_bib0005","unstructured":"Stewart BW, Wild CP, editors. World Cancer Report 2014. International Agency for Research on Cancer; 2014."},{"issue":"3","key":"10.1016\/j.prp.2017.10.016_bib0010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.prp.2017.10.016_bib0015","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.prp.2017.10.016_bib0020","doi-asserted-by":"crossref","first-page":"5489","DOI":"10.1158\/1078-0432.CCR-10-1371","article-title":"Reciprocal and complementary role of MET amplification and EGFR T790 M mutation in acquired resistance to kinase inhibitors in lung cancer","volume":"16","author":"Suda","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.prp.2017.10.016_bib0025","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1158\/1535-7163.MCT-10-0625","article-title":"Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790 M mutation","volume":"9","author":"Rho","year":"2010","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.prp.2017.10.016_bib0030","doi-asserted-by":"crossref","first-page":"S1069","DOI":"10.1016\/j.jtho.2016.11.1496","article-title":"P.2. 06-003 A phase Ib study of the combination of Afatinib and Ruxolitinib in EGFR mutant non-small cell lung cancer (NSCLC) progressed on EGFR-TKI","volume":"12","author":"Park","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2017.10.016_bib0035","first-page":"19","article-title":"Thalidomide in pulmonary disease","volume":"22","author":"Vigeland","year":"2016","journal-title":"Int. J. Med. Biol. Front."},{"issue":"4","key":"10.1016\/j.prp.2017.10.016_bib0040","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cncr.20821","article-title":"Thalidomide in the treatment of patients with hepatocellular carcinoma","volume":"103","author":"Patt","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.prp.2017.10.016_bib0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4103\/0366-6999.174497","article-title":"Thalidomide-based regimens for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis","volume":"129","author":"Lyu","year":"2016","journal-title":"Chin. Med. J."},{"issue":"1","key":"10.1016\/j.prp.2017.10.016_bib0050","first-page":"39","article-title":"The efficacy and safety of thalidomide-based therapy in patients with advanced non-small cell lung cancer: a meta-analysis","volume":"18","author":"Liu","year":"2014","journal-title":"Contemp. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2017.10.016_bib0055","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.prp.2017.10.016_bib0060","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","article-title":"Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance","volume":"15","author":"Naumov","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.prp.2017.10.016_bib0065","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/17476348.2016.1164603","article-title":"Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer","volume":"10","author":"Noda","year":"2016","journal-title":"Expert Rev. Respir. Med."},{"issue":"21","key":"10.1016\/j.prp.2017.10.016_bib0070","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and common secondary T790 M mutations in epidermal growth factor receptor\u2013mutant lung adenocarcinomas with acquired resistance to kinase inhibitors","volume":"12","author":"Balak","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"22","key":"10.1016\/j.prp.2017.10.016_bib0075","doi-asserted-by":"crossref","first-page":"7519","DOI":"10.1158\/1078-0432.CCR-08-0151","article-title":"Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma","volume":"14","author":"Bean","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.prp.2017.10.016_bib0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3892\/ol.2013.1705","article-title":"Acquired resistance L747S mutation in an epidermal growth factor receptor-tyrosine kinase inhibitor-na\u00efve patient: a report of three cases","volume":"7","author":"Yamaguchi","year":"2014","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.prp.2017.10.016_bib0085","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1158\/0008-5472.CAN-05-3090","article-title":"EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms","volume":"66","author":"Pore","year":"2006","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.prp.2017.10.016_bib0090","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.prp.2017.10.016_bib0095","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol."},{"issue":"31","key":"10.1016\/j.prp.2017.10.016_bib0100","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1200\/JCO.2012.47.3983","article-title":"ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer","volume":"31","author":"Johnson","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2017.10.016_bib0105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamaoncol.2015.4921","article-title":"First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the aspiration study","volume":"2","author":"Park","year":"2016","journal-title":"JAMA Oncol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033817308798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033817308798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T12:24:18Z","timestamp":1540470258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033817308798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0344033817308798"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2017.10.016","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of erlotinib and thalidomide in advanced NSCLC patients with acquired resistance to erlotinib: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2017.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}